Expedition 74: From A Microscopic Preflight Image Of Hematopoietic Cells To A BioServe Microgravity Bioreactor Aboard The Space Station. The InSPA-StemCellEX-H2 Investigation Is No Longer Studying Whether Stem Cells Grow Better In Space. It Is Demonstrating Large-Scale Clinical Production
According to NASA, Expedition 74 astronauts aboard the International Space Station are conducting the InSPA-StemCellEX-H2 investigation; a research programme that has moved beyond feasibility studies and into demonstrating large-scale production of blood stem cells for direct pharmaceutical and clinical use on Earth.
NASA astronaut Jessica Meir was photographed working on the investigation inside the Life Sciences Glovebox, handling samples that will be frozen and returned to Earth for analysis.
The work is a collaboration between NASA’s In-Space Production Applications programme, BioServe Space Technologies at the University of Colorado Boulder, and the Mayo Clinic, which supplied the preflight microscopic imaging of hematopoietic stem cells used in the investigation.
To understand why this matters, the biology requires a brief explanation. Hematopoietic stem cells; the blood stem cells at the centre of this research are the master cells of the human blood and immune system. From a single progenitor cell, the entire cascade of blood components is generated: red blood cells carrying oxygen, white blood cells forming immune defences, platelets enabling clotting.
For patients with leukaemia undergoing chemotherapy, the treatment deliberately destroys the bone marrow to kill cancer cells and then requires a stem cell transplant to rebuild the patient’s entire blood system from scratch. The quality, quantity, and preserved differentiation potential of the transplanted stem cells is the difference between recovery and relapse.
Why Earth-based stem cell expansion has limits. The problem with producing these cells on Earth is well-established within haematology. The process of expanding stem cells in lab culture; growing large quantities from a small initial sample consistently degrades the cells’ potency.
As Dr. Tobias Niederwieser, assistant research professor at BioServe Space Technologies within the University of Colorado Boulder, explains: “Earth-produced cells lose their ability to form the different cells in our blood system, like red and white blood cells or platelets, which are critical for leukaemia patients that receive stem cells to build up their blood system after chemotherapy.”
The more the cells are expanded in terrestrial conditions, the less they retain the undifferentiated, pluripotent character that makes them therapeutically useful. This is the core biological obstacle in stem cell medicine; expansion and quality are in tension. More cells means worse cells.
What microgravity changes. The ISS investigation rests on a key hypothesis, supported by earlier rounds of space-based stem cell research: that the microgravity environment aboard the space station fundamentally alters the conditions under which stem cells divide and replicate.
On Earth, cells in suspension culture experience sedimentation; they sink, cluster, interact with surfaces, and receive directional gravitational cues that influence their differentiation patterns.
In microgravity, none of that occurs. Cells float freely, experience far more uniform nutrient and gas exchange, and are shielded from the mechanical stresses that gravity-related sedimentation imposes. Dr. Niederwieser notes: “The microgravity environment in space is much more suitable for keeping the stem cells in their high-quality state during expansion.”
Scientists predict that growing cells in space will produce higher expansion potential; more cells produced per starting sample combined with a lower risk of rejection when the cells are used in patients, because their immune tolerance profile is better preserved.
The progression from earlier studies to large-scale production. The InSPA-StemCellEX-H2 designation marks the continuation and escalation of a research programme that has been refining hardware and protocols over multiple ISS expeditions.
Previous studies in the InSPA-StemCellEX series focused on fine-tuning the bioreactor hardware; the BioServe-developed microgravity bioreactor that maintains cell cultures in the space station environment and establishing baseline data on how human haematopoietic stem cells behave in microgravity.
The H2 iteration is not a feasibility study. It is a demonstration of clinical-scale production; an attempt to show that the quantity and quality of cells that can be produced aboard the ISS is sufficient for direct pharmaceutical and clinical application on Earth.
The distinction matters enormously. Moving from “stem cells can survive and divide in space” to “we can produce enough high-quality stem cells in space to treat patients” is the difference between scientific curiosity and a medical supply chain.
The diseases this addresses are among the most lethal and undertreated. NASA notes that this research could create long-term cell supplies for patients suffering from fatal blood disorders, various blood cancers, or severe immune diseases, and enable more reliable and accessible therapies. The burden of these conditions is enormous.
Leukaemia alone kills approximately 300,000 people globally each year. Aplastic anaemia, sickle cell disease, thalassaemia, and severe combined immunodeficiency (SCID) all represent conditions where haematopoietic stem cell transplants are the only curative or life-extending option.
The current global supply of high-quality, transplant-ready stem cells is insufficient for patient demand. Donor matching, cell quality degradation during expansion, and geographic distribution of specialised cell production facilities all create access gaps.
A space-based production pathway through the ISS, if it yields consistently higher-quality cells that survive cryogenic storage and transport, addresses multiple bottlenecks simultaneously.
The broader in-space manufacturing context. The ISS has become an operational test bed for a generation of biotechnology manufacturing experiments that exploit the unique properties of the microgravity environment. Protein crystallisation in space has produced higher-purity pharmaceutical crystals than Earth-based production allows.
Cell spheroid and organoid growth in microgravity produces three-dimensional tissue structures that more closely replicate in vivo biology than the flat, gravity-affected cultures that standard Earth labs produce. The InSPA-StemCellEX programme aboard the ISS, sits at the leading edge of this trend using the space station not as a destination for scientific observation but as a precision manufacturing facility whose product is shipped back to Earth for patient use.
Dr. Niederwieser’s statement is the clearest articulation of this posture: “The end result is really to benefit patients in hospitals here on Earth.”
The commercial and regulatory pathway ahead. For space-manufactured stem cells to reach clinical use, the journey from the ISS bioreactor to a patient’s bone marrow involves a chain of steps that the research must validate before the FDA will consider any biological product manufactured in orbit for human therapeutic use.
Cryogenic preservation protocols for cells produced aboard the ISS must demonstrate equivalence to Earth-manufactured standards. Return logistics; SpaceX Dragon splashdowns, rapid transfer to cell processing facilities, cold-chain integrity must be documented and validated.
Cell potency assays must confirm that microgravity-expanded cells retain their therapeutic superiority from space to cryopreservation to thaw and infusion. None of these steps is trivial. None has been established as routine. The current investigation is generating the data that makes each of them possible to validate.
The verdict. The InSPA-StemCellEX-H2 investigation is a quiet milestone in the history of medical manufacturing. It represents the first serious attempt to demonstrate clinical-scale production of a therapeutically critical biological product in the microgravity environment of low Earth orbit not for the purpose of advancing space medicine but for the purpose of improving Earth medicine.
If the data returned by Expedition 74 support the hypothesis that microgravity-expanded stem cells are superior in quantity and quality to anything achievable on Earth, the supply chain implications for haematological oncology and immune disease treatment will be transformative. The space station was built as a laboratory. This investigation is turning it into a pharmacy.
To check out our previous coverage on space science, ISS research, and the commercial space economy, read our articles here.
